Crispr Therapeutics

Yahoo Finance • 4 days ago

Want to Invest in OpenAI Before Its Blockbuster IPO? Here's How to Do It.

Key Points OpenAI is the creator of ChatGPT, which is one of the world's most popular artificial intelligence (AI) chatbots. OpenAI is a private company, so everyday investors can't directly buy its shares, but plans for an initial publi... Full story

Yahoo Finance • 6 days ago

Meet Cathie Wood's Flagship Ark Innovation ETF, Which Has Crushed the S&P 500 Over the Last 12 Months

Ark Investment Management operates a dozen exchange-traded funds (ETFs) that invest in companies that are pursuing innovations across an array of technologies. Some of these funds have a specific focus in areas like artificial intelligence... Full story

Yahoo Finance • 7 days ago

This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area

CRISPR Therapeutics(NASDAQ: CRSP) has significantly lagged broader equities over the past five years. There are several reasons for that. Challenging economic conditions have led investors to rotate their money out of somewhat speculative... Full story

Yahoo Finance • 8 days ago

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics AG ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Virtual Healthcar... Full story

Yahoo Finance • 8 days ago

Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?

Investors looking for stocks that can turn a modest portfolio into a multimillion-dollar nest egg often find what they're looking for in the biotech industry. For several years, CRISPR Therapeutics(NASDAQ: CRSP) has been attracting investm... Full story

Yahoo Finance • 12 days ago

Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM

Cathie Wood’s ARK Invest funds have delivered mixed performance in the recent period, with ARK Space & Defense Innovation ETF (ARKX [https://seekingalpha.com/symbol/ARKX]) up 1.27% and ARK Autonomous Technology & Robotics ETF (ARKQ [https:... Full story

Yahoo Finance • 19 days ago

Cathie Wood Dumps $2.1 Million in This 'Magnificent Seven' Stock

This article first appeared on GuruFocus. Cathie Wood's ARK Invest sold shares of Meta Platforms (NASDAQ:META) and added to its position in Tempus AI (NASDAQ:TEM). The investment firm offloaded 3,578 Meta shares valued at about $2.1 mill... Full story

Yahoo Finance • 21 days ago

Cathie Wood sells $5.9M in Circle shares days before stock crash

We write about Cathie Wood a lot, and for good reason. She has been one of Wall Street’s earliest and most consistent believers in crypto. Long before Bitcoin and Ethereum became institutional assets, Wood was building exposure through co... Full story

Yahoo Finance • 23 days ago

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?

Key Points CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable. CRISPR's financial positio... Full story

Yahoo Finance • 27 days ago

BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?

Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on BCRX. BioCryst Pharmaceuticals, Inc.'s share was trading at $9... Full story

Yahoo Finance • 29 days ago

From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here

Quick Read CRISPR Therapeutics (CRSP) holds $2.56B in pro forma cash after a $600M convertible note issuance, funding pipeline advancement through clinical development without near-term capital raises. CASGEVY gene therapy generated $116M... Full story

Yahoo Finance • 29 days ago

Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now?

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months. Cathie Wood’s ARK increased its stake in... Full story

Yahoo Finance • last month

Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?

Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.'s share was trading... Full story

Yahoo Finance • last month

Cathie Wood buys $2 million of tumbling AI stock

Cathie Wood, chief of Ark Investment Management, doesn’t give up on her favorite stocks easily. That’s what she just did, buying one of her top holdings that’s down 15% year-to-date. Wood gained a reputation after the flagship Ark Innova... Full story

Yahoo Finance • last month

Here is Why CRISPR Therapeutics (CRSP) Appears so Good

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) from $32 to $33, while ma... Full story

Yahoo Finance • last month

Cathie Wood buys $27 million of battered tech stock

Cathie Wood, head of Ark Investment Management, likes to make bold bets, even when the stocks she picks are down for a while. That’s what she just did, buying a stock that’s down more than 30% year to date. Wood often views sharp pullbac... Full story

Yahoo Finance • last month

CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value of over $551 million as of Q4 2025. The gene-editing company remains on analysts’ radar and currently carries a... Full story

Yahoo Finance • last month

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood has made a name for herself as an innovation-focused growth investor, and her leadership as the founder and CEO of Ark Invest has led some investors to pay close attention to the equity purchases and sales in the various exchan... Full story

Yahoo Finance • 2 months ago

Key deals this week: KORE, TopBuild, Equinix, PayPal and more

[M A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] fengdr Here's a list of key deals reported across sectors this week: * KORE Group Holdings (KORE [https://seekingalpha.com/symbol/KORE]) on Friday... Full story

Yahoo Finance • 2 months ago

Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory

We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX. Celldex Therapeutics, Inc.'s share was trading at $30.82 as of February 25th.test, cancer,... Full story